This is a study to determine the safety and tolerability of pantoprazole (Protonix) in infants between the ages 1 month through 11 months with presumed gastroesophageal reflux disorder. This national study is currently recruiting patients.
Read moreYes, acid-reducing medications can cause bone loss. Many medications and medical disorders can cause bone loss; but in this article... Read more »
This is a study to determine the minimal clinical difference in gastroesophageal reflux disorder (GERD) patients using pantoprazole (Protonix) versus... Read more »
Wyeth Pharmaceuticals will be conducting a clinical trial to evaluate the use of pantoprazole (Protonix) in children ages 1 to 5. This national study... Read more »
Drugmakers Atlana and Wyeth have sued Schwarz Pharma to stop the rival company from making a generic form of Protonix (pantoprazole). Schwarz Pharma... Read more »
Drugmaker Teva has received tentative approval for a generic form of Protonix delayed-release tablets (pantoprazole sodium). Final approval is... Read more »
Drugmaker Wyeth has launched a generic version of their acid-reflux medication Protonix. The launch comes in response to the generic version of... Read more »